IPTp-SP

Kenya Medical Research Institute · FDA-approved active Small molecule

IPTp-SP is a Antifolate antimalarial combination Small molecule drug developed by Kenya Medical Research Institute. It is currently FDA-approved for Malaria prevention in pregnant women (intermittent preventive therapy). Also known as: Fansidar, SP.

IPTp-SP is a combination of intermittent preventive treatment using sulfadoxine-pyrimethamine to prevent malaria infection in pregnant women by inhibiting folate synthesis in the malaria parasite.

IPTp-SP is a combination of intermittent preventive treatment using sulfadoxine-pyrimethamine to prevent malaria infection in pregnant women by inhibiting folate synthesis in the malaria parasite. Used for Malaria prevention in pregnant women (intermittent preventive therapy).

At a glance

Generic name	IPTp-SP
Also known as	Fansidar, SP
Sponsor	Kenya Medical Research Institute
Drug class	Antifolate antimalarial combination
Target	Dihydrofolate reductase (DHFR)
Modality	Small molecule
Therapeutic area	Infectious Disease / Parasitology
Phase	FDA-approved

Mechanism of action

IPTp-SP (Intermittent Preventive Therapy in pregnancy with Sulfadoxine-Pyrimethamine) works by administering therapeutic doses of the antimalarial drug sulfadoxine-pyrimethamine at scheduled intervals during pregnancy. Sulfadoxine-pyrimethamine inhibits dihydrofolate reductase in Plasmodium parasites, disrupting folate metabolism and preventing parasite replication. This approach reduces parasitemia, placental malaria, and associated adverse pregnancy outcomes including low birth weight and maternal anemia.

Approved indications

• Malaria prevention in pregnant women (intermittent preventive therapy)

Common side effects

• Nausea
• Vomiting
• Abdominal discomfort
• Rash

Key clinical trials

• Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
• Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in South Sudan (PHASE3)
• Chemoprevention Efficacy Study in Burkina Faso (PHASE4)
• TIPTOP Sulfadoxine-pyrimethamine (SP) Drug Resistance Study
• The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract (PHASE3)
• Additional Screening With Sensitives RDTs and Malaria (PHASE3)
• Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) (PHASE3)
• Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IPTp-SP CI brief — competitive landscape report
• IPTp-SP updates RSS · CI watch RSS
• Kenya Medical Research Institute portfolio CI

Frequently asked questions about IPTp-SP

What is IPTp-SP?

IPTp-SP is a Antifolate antimalarial combination drug developed by Kenya Medical Research Institute, indicated for Malaria prevention in pregnant women (intermittent preventive therapy).

How does IPTp-SP work?

IPTp-SP is a combination of intermittent preventive treatment using sulfadoxine-pyrimethamine to prevent malaria infection in pregnant women by inhibiting folate synthesis in the malaria parasite.

What is IPTp-SP used for?

IPTp-SP is indicated for Malaria prevention in pregnant women (intermittent preventive therapy).

Who makes IPTp-SP?

IPTp-SP is developed and marketed by Kenya Medical Research Institute (see full Kenya Medical Research Institute pipeline at /company/kenya-medical-research-institute).

Is IPTp-SP also known as anything else?

IPTp-SP is also known as Fansidar, SP.

What drug class is IPTp-SP in?

IPTp-SP belongs to the Antifolate antimalarial combination class. See all Antifolate antimalarial combination drugs at /class/antifolate-antimalarial-combination.

What development phase is IPTp-SP in?

IPTp-SP is FDA-approved (marketed).

What are the side effects of IPTp-SP?

Common side effects of IPTp-SP include Nausea, Vomiting, Abdominal discomfort, Rash.

What does IPTp-SP target?

IPTp-SP targets Dihydrofolate reductase (DHFR) and is a Antifolate antimalarial combination.

Related

• Drug class: All Antifolate antimalarial combination drugs
• Target: All drugs targeting Dihydrofolate reductase (DHFR)
• Manufacturer: Kenya Medical Research Institute — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Parasitology
• Indication: Drugs for Malaria prevention in pregnant women (intermittent preventive therapy)
• Also known as: Fansidar, SP